Danielle Brander, MD
Recent developments in the treatment of patients with chronic lymphocytic leukemia (CLL) have created new, unanswered questions and left clinicians scrambling to keep up with the pace of change, said Danielle Brander, MD. However, she said that is a good problem to have.
, she highlighted how recent advances are changing the field of CLL and what it means for patients and their oncologists.
OncLive: Can you provide an overview on the current treatment landscape for CLL?
: There have been a lot of changes in the treatment options available for patients with CLL. For frontline treated patients, what has changed the most in the past 5 years is that we're trying to identify both the patients who may still be both eligible for and benefit from long-term chemoimmunotherapy. [These are] young, favorable-risk patients—IGHV
mutated, no high-risk deletion 11q or deletion 17p. [These patients] can sometimes get very long-term, 10- or 12-year plus, remissions from frontline chemotherapy with fludarabine, cyclophosphamide, and rituximab (Rituxan; FCR).
... to read the full story